Sunitinib‐induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour
Summary What is known and objective Sunitinib can improve progression‐free survival and overall survival in patients with advanced pancreatic neuroendocrine tumor (PNET). From clinical trial, most commonly reported adverse events of sunitinib were neutropenia (12%), diarrhea (10%), asthenia (7%), er...
Saved in:
Published in | Journal of clinical pharmacy and therapeutics Vol. 38; no. 4; pp. 327 - 329 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Blackwell
01.08.2013
Hindawi Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
What is known and objective
Sunitinib can improve progression‐free survival and overall survival in patients with advanced pancreatic neuroendocrine tumor (PNET). From clinical trial, most commonly reported adverse events of sunitinib were neutropenia (12%), diarrhea (10%), asthenia (7%), erythrodysesthesia (7%), hypertension (7%) and thrombocytopenia (6%).
Case summary
We report a patient with PNET with liver metastases who developed hyperammonemia with a low dosage of sunitinib probably contributed by the presence of liver metastases.
What is new and conclusions
We would like to draw attention to the potential risk of sunitinib induced hyperammonemic encephalopathy even with a low dosage of sunitinib. The absence of sunitinib‐induced hyperammonemia during its initial course does not rule out this possibility if there is increased in liver metastases. We suggest checking the ammonia level if patient on sunitinib presented with altered sensorium even if the liver function is normal. |
---|---|
Bibliography: | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
ISSN: | 0269-4727 1365-2710 |
DOI: | 10.1111/jcpt.12054 |